Evaluation of Inflammatory Cytokines During COVID-19

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04824495

Enrollment

100

Registered

2021-04-01

Start date

2021-01-07

Completion date

2021-12-31

Last updated

2021-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The aim of this study is to evaluate pro-inflammatory cytokines as well as microvesicles during the course of SARS-CoV2 infection in the context of clinical parameters.

Detailed description

In this prospective trial, 100 patients with an acute SARS-CoV2 infection are enrolled. After confirmation of COVID-19, blood samples are taken for evaluation of various inflammatory cyokines and microvesicles at day 1, 5, 9 and 13 during hospitalisation and are interpreted in the context of clinical parameters.

Interventions

DIAGNOSTIC_TESTBlood sample

Blood samples at different timepoints during SARS-CoV2 infection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age \> 18 years * Confirmation of acute SARS-CoV2 infection * Ability to provide informed consent

Design outcomes

Primary

Measure	Time frame
Cytokine level in context with clinical parameters	2 weeks

Countries

Austria

Contacts

Primary ContactDaniela Gompelmann

daniela.gompelmann@meduniwien.ac.at0043 1 40400 47730

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026